创新药彻底火了！ 截至7月29日，基金市场涌现16只"翻倍基"，全部都与创新药主题相关，其中汇添富基金的张韡管理的汇添富香港优势精选A以138.9%的傲人涨幅问鼎冠 军，长城基金的梁福睿管理的长城医药产业精选A以129.35%的涨幅拿下亚军。中银基金的郑宁管理的中银港股通医药A以119.64%涨幅排名第三名。 汇添富国证港股通创新药ETF、万家中证港股通创新药ETF、广发中证香港创新药ETF和华泰柏瑞恒生创新药ETF分别涨107.67%、106.87%、106.39%、 106.36%。 | 序号 | 证券代码 | 证券简称 | 今年净值增长率% | 合并规模(亿元) | | --- | --- | --- | --- | --- | | 1 | 470888.OF | 汇添富香港优势精选A | 138.90 | 2.19 | | 2 | 022286.OF | 长城医药产业精选A | 129.35 | 11.32 | | ਤੋ | 020397.OF | 中银港股通医药A | 119.64 | 7.40 | | 4 | 015915.OF | 永赢医药创新智选A | 114.79 | 30.43 | | 5 ...

Core Insights - The National Medical Products Administration (NMPA) approved 43 new class 1 innovative drugs in the first half of 2025, a 59% increase year-on-year, nearing the total of 48 approvals for the entire year of 2024 [1] - The approval of innovative drugs is accelerating, with expectations for a record high in 2025 [1] Drug Type Distribution - Chemical drugs lead with 24 varieties, accounting for 56% of approvals; biological products follow with 14 varieties (32%); and traditional Chinese medicine and natural products account for 5 varieties (12%) [2] - The industry is transitioning from a "single-pole dominance" to a "multi-polar balance" [2] Therapeutic Area Insights - Oncology drugs dominate with 20 varieties, making up 47% of approvals; anti-infective drugs, traditional Chinese medicine, and endocrine/metabolic drugs each have 5 varieties (12%) [2] - The approval landscape shows a diverse range of therapeutic areas, with notable mentions for rare diseases and pediatric drugs [3] Review and Approval Process - 17 new drugs, approximately 40% of the total, received breakthrough therapy designation, including 8 biological products and 8 chemical drugs [2] - The NMPA is prioritizing the development of drugs for rare diseases and pediatric use, with specific plans in place for expedited review [3] Policy Support for Innovation - China's pharmaceutical innovation is rapidly advancing, with the country holding about 25% of the global innovative drug pipeline [4] - Recent policy measures, such as the implementation of the "Full Chain Support for Innovative Drug Development" plan, have significantly improved the speed of new drug inclusion in medical insurance [4] Future Initiatives - The NMPA plans to implement further measures to support innovative drug development, focusing on clinically valuable products and global synchronization of research [5] - Efforts will include optimizing review processes, enhancing intellectual property protections, and aligning with international standards to facilitate global competitiveness [5]

Investment Rating - The report suggests a focus on sectors such as innovative pharmaceuticals, AI hardware, and childcare subsidies, indicating a positive outlook for these areas [4][18]. Core Insights - The market is experiencing a rebound, with the North Exchange A-share trading volume reaching 26.42 billion yuan, an increase of 2.19 billion yuan from the previous trading day. The North Exchange 50 Index closed at 1465.32, up 0.68%, with a PE_TTM of 68.41 times [2][8]. - The report highlights strong performance in the innovative pharmaceutical sector, driven by national childcare subsidy policies and industry R&D advancements, with companies like Sanmian Gene seeing a rise of over 20% [4][15]. - The report anticipates a mixed market in the short term but expects resilience in the medium to long term due to policy dividends and industrial upgrades [4]. Summary by Sections Market Review - On July 29, the North Exchange A-share trading volume was 26.42 billion yuan, with 268 companies listed. Among these, 98 companies rose, 8 remained flat, and 162 fell [2][15]. - The top five gainers included Sanmian Gene (20.80%), Jikang Instrument (20.40%), and Huaitong New Materials (14.20%) [15][17]. Important News - The establishment of the third state-owned automobile enterprise, China Chang'an Automobile Group, aims to enhance the development of intelligent connected new energy vehicles [18]. - The report also mentions the establishment of a new semiconductor photomask company in Anhui, which will focus on producing photomasks for 28nm and above process nodes [19]. Key Company Announcements - Yintu Network received 10 software copyright registration certificates from the National Copyright Administration [3][24]. - Zhongcheng Technology signed a cooperation agreement with China Mobile for a big data cloud platform service project worth 50.52 million yuan [3][20]. - Sanmian Gene announced the approval of a new drug, recombinant human interferon α1b spray, by the National Medical Products Administration [3][22].

而展望2025年及后续几年： 1）需求端随着全球步入降息周期，已逐步复苏，业绩端陆续兑现； 2）供给端因部分头部企业放缓扩产进程，中小企业部分关停，产能持续去化，行业整体趋向动态平衡 发展； 3）业绩端，2025年部分企业大订单高基数影响已基本消化出清，CXO行业将进入平稳增长阶段。 从外部宏观环境来看，情况也有所缓解，估值陆续修复。2025年4月受关税政策冲击，部分出海CXO公 司出现较大幅度回撤。从业务层面看，CRO业务属服务类业务，不受商品关税影响；CDMO特别是商 业化项目直发美国市场的占比较少，预计影响有限。供应链的转移非一朝一夕能够落地的。目前看出海 CXO仍然是增长确定性更强的，同时部分企业已积极采取措施以规避风险，如剥离美国受限业务，以 欧洲、东南亚作为国际化产能新方向等。随着中美关税的边际缓和，CXO企业已逐步迎来估值修复。 另外，可关注内需修复及行业出清后集中度提升。国内创新药支持政策频出，行业需求有望逐步回暖。 同时H股市场的回暖、科创板第五套标准的重启、创新药BD的火热等均为早期研发的需求复苏提供新 动能。此外国内CXO企业经历几年需求遇冷、价格竞争，倒逼企业降本增效，成本结构的改善具 ...

Market Overview - The Shanghai Composite Index rose by 0.17% to close at 3615.72 points, while the Shenzhen Component Index fell by 0.77% and the ChiNext Index dropped by 1.62%. The total market turnover exceeded 1.87 trillion yuan [2][4]. Sector Performance - Major sectors showed mixed performance, with banking, insurance, and steel stocks rising in the morning but retreating in the afternoon. The three-child policy concept stocks gained momentum, particularly Beiyinmei, which hit the daily limit within three minutes of trading [4][5]. - The battery, digital currency, diversified finance, military restructuring, and rare earth permanent magnet sectors experienced a collective pullback [4]. Baby and Maternal Sector - The baby and maternal sector saw significant activity, with stocks like Beiyinmei, Sunshine Dairy, and Taimoshi reaching their daily limits. Beiyinmei closed at 7.39 yuan per share, marking a 9.97% increase [5][6]. - The National Health Commission announced plans for a childcare subsidy system, with an initial budget of approximately 90 billion yuan for this year, which is expected to stimulate demand in the baby and maternal market [9]. Pharmaceutical Sector - The pharmaceutical sector remained active, particularly in innovative drugs, with companies like Nanjing New Pharmaceutical and Chenxin Pharmaceutical hitting their daily limits. The industry is transitioning towards a focus on profitability rather than just growth narratives [15][21]. - The innovative drug market is projected to continue its upward trend, with significant growth expected in the coming years, driven by policy support [10][21]. New Listings - The newly listed company N Hanhigh saw a dramatic increase of 418.47% on its first trading day, closing at 80 yuan per share. The company specializes in home hardware and outdoor furniture [22].

30日，沪指盘中震荡拉升，一度创年内新高；深证成指、创业板指弱势下探，场内超3500股飘绿。 光大证券指出，去年9月以来的市场行情已从政策驱动逐步转向基本面与流动性驱动，未来市场行情演 绎的节奏或可参照2019年。展望下半年，市场仍存在一些预期差，如短期基本面改善的持续性、资金持 续流入及新兴产业发展带来的机遇等。因此光大证券认为，下半年市场将开启下一阶段上涨行情，并有 望突破2024年下半年的阶段性高点。 （文章来源：证券时报网） 截至收盘，沪指涨0.17%报3615.72点，深证成指跌0.77%报11203.03点，创业板指跌1.62%报2367.68点， 上证50指数涨0.38%，沪深北三市合计成交18713亿元。 盘面上看，券商、有色、汽车、地产等板块走低，旅游、石油、影视、乳业股拉升，海洋经济、创新药 概念等活跃。 ...

Core Insights - The total trading volume of ETFs in the market has reached 350.245 billion yuan, with various types contributing differently to this total [1] Trading Volume Breakdown - Stock ETFs accounted for 164.176 billion yuan of the total trading volume [1] - Bond ETFs contributed 95.330 billion yuan [1] - Money market ETFs had a trading volume of 23.855 billion yuan [1] - Commodity ETFs recorded a trading volume of 6.746 billion yuan [1] - QDII ETFs reached a trading volume of 60.136 billion yuan [1] Top Performing ETFs - The highest trading volumes among non-money market ETFs were recorded by: - E Fund CSI Hong Kong Securities Investment Theme ETF (513090) with 19.778 billion yuan [1] - GF CSI Hong Kong Innovative Medicine (QDII-ETF) (513120) with 17.418 billion yuan [1] - Huaxia Hang Seng Technology ETF (QDII) (513180) with 6.118 billion yuan [1]

Group 1 - The innovative pharmaceutical ETF (560900) experienced a significant trading volume with a turnover of 33.85% and a transaction value of 24.0583 million yuan, marking a new high since its listing [1] - The tracking index, the CSI Innovative Pharmaceutical Industry Index (931152), saw a slight decline of 0.23%, while constituent stocks exhibited mixed performance, with Dongcheng Pharmaceutical (002675) leading with a 10.00% increase [1] - Over the past week, the innovative pharmaceutical ETF (560900) accumulated a rise of 7.41%, reaching a new scale of 70.7947 million yuan and a new share count of 69.9691 million [1] Group 2 - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of 2025, reflecting a year-on-year growth of 20.64%, with a non-IFRS net profit of 5.58 billion yuan, up 26.5% [2] - The company's gross margin improved to 44.5%, an increase of 4.7 percentage points year-on-year, with its TIDES business showing remarkable growth, achieving a revenue of 5.03 billion yuan, up 141.6% [2] - The global demand for innovative drug outsourcing is recovering, enhancing the competitiveness of Chinese CXO companies, and the industry is experiencing a steady rebound [2]

Group 1 - The A-share market is experiencing a sustained upward trend, with the Shanghai Composite Index stabilizing above 3600 points and the CSI 300 Index showcasing low valuation and high dividend characteristics [1] - The E Fund CSI 300 ETF Fund (Class A: 110020; Class C: 007339) serves as a low-cost tool for tracking the CSI 300 Index, currently valued at a price-to-earnings ratio of 13.34 and a dividend yield of 2.97%, providing investors with an efficient entry point into core Chinese economic assets [1] - The current market hotspots are focused on three main lines: the performance reversal in innovative drugs and CROs, the sustained high demand in AI computing power chains, and the military industry benefiting from the conclusion of the 14th Five-Year Plan and increased military trade [1] Group 2 - The E Fund CSI 300 ETF Fund closely tracks the CSI 300 Index, covering key sectors such as finance, consumption, technology, and industry, with constituent stocks accounting for less than 6% of A-shares but representing nearly 48% of market capitalization [1] - The fund's annual management fee rate of 0.15% is considered a benchmark in the industry, with a minimum investment of 10 yuan for external subscriptions, ensuring high liquidity for efficient entry and exit [1] - The CSI 300 Index is currently around 4167 points, indicating over 40% potential upside to its 2021 peak, making index-based investment a strategy to mitigate individual stock volatility risks during a slow bull market [1] Group 3 - The E Fund CSI 300 ETF Fund is suitable for long-term holding, helping investors avoid common pitfalls such as entering with light positions and then heavily chasing high prices [1] - The "New National Nine Articles" policy reinforces the high-quality development of the capital market, with the CSI 300 Index expected to continue attracting global capital as a stabilizing force in the A-share market [1] - Investors are encouraged to utilize this fund for low-position layouts to capture the benefits of economic recovery [1]

Group 1 - The Hang Seng Biotechnology Index (HSHKBIO) has seen a strong increase of 1.88%, with notable gains from constituent stocks such as MicroPort Medical (00853) up 8.63%, and Stone Pharmaceutical Group (01093) up 7.40% [1] - The Hang Seng Biotechnology ETF (513280) has risen by 3.00%, marking its third consecutive increase, with a latest price of 1.34 HKD and a weekly cumulative increase of 8.89% [1] - The trading volume for the Hang Seng Biotechnology ETF was active, with a turnover of 34.45% and a transaction value of 161 million HKD, indicating strong market participation [1] Group 2 - The Hang Seng Biotechnology ETF has experienced a significant increase in shares, growing by 2 million shares over the past week, ranking in the top third among comparable funds [2] - The ETF has seen continuous net inflows over the last three days, with a peak single-day net inflow of 3.83 million HKD, totaling 8.73 million HKD in net inflows [2] Group 3 - Over the past year, the net value of the Hang Seng Biotechnology ETF has increased by 130.59%, ranking 3rd out of 122 QDII equity funds, placing it in the top 2.46% [3] - WuXi Biologics announced the construction of a modular biomanufacturing facility in Singapore, which is part of a strategic collaboration with Pharmadule Morimatsu [3] - The latest report from Zhongyin Securities suggests focusing on three main lines: 1) sectors with stable growth such as medical devices and pharmaceuticals, 2) the CXO sector and medical equipment expected to see a turnaround, and 3) innovative fields related to national medical insurance negotiations [3] Group 4 - The Hang Seng Biotechnology ETF (513280) is highlighted as the only ETF tracking the Hang Seng Biotechnology Index to have received net inflows this year, with the lowest management fee of 0.15% per year among Hong Kong pharmaceutical ETFs [4]